

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Clarus Lifesciences II, L.P.</u> <hr/> (Last) (First) (Middle) C/O CLARUS VENTURES, LLC 101 MAIN STREET SUITE 1210 <hr/> (Street) CAMBRIDGE MA 02142 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CATABASIS PHARMACEUTICALS</u> <u>INC [CATB]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/30/2015</u>	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/30/2015		C		1,618,676	A	(1)	1,618,676	D ⁽²⁾⁽³⁾	
Common Stock	06/30/2015		C		757,117	A	(1)	2,375,793	D ⁽²⁾⁽³⁾	
Common Stock	06/30/2015		P		376,695	A	\$12	2,752,488	D ⁽²⁾⁽³⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Preferred Stock	(1)	06/30/2015		C		20,800,000		(1)	(1)	Common Stock	1,618,676	\$0	0	D ⁽²⁾⁽³⁾	
Series B Preferred Stock	(1)	06/30/2015		C		9,728,971		(1)	(1)	Common Stock	757,117	\$0	0	D ⁽²⁾⁽³⁾	

1. Name and Address of Reporting Person* <u>Clarus Lifesciences II, L.P.</u> <hr/> (Last) (First) (Middle) C/O CLARUS VENTURES, LLC 101 MAIN STREET SUITE 1210 <hr/> (Street) CAMBRIDGE MA 02142 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person*		
Clarus Ventures II GP, L.P.		
(Last)	(First)	(Middle)
C/O CLARUS VENTURES, LLC 101 MAIN STREET SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		

1. Name and Address of Reporting Person*		
Clarus Ventures II, LLC		
(Last)	(First)	(Middle)
C/O CLARUS VENTURES, LLC 101 MAIN STREET SUITE 1210		
(Street)		
CAMBRIDGE	MA	02142
(City) (State) (Zip)		

Explanation of Responses:

1. The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
2. These shares are owned directly by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest.
3. Each of Nicholas Galakatos, Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.

[By: /s/ Robert Liptak,
Manager of Clarus Ventures II,
LLC, general partner of Clarus
Ventures II GP, L.P., general
partner of Clarus Lifesciences
II, L.P.](#) 06/30/2015

[By: /s/ Robert Liptak,
Manager of Clarus Ventures II,
LLC, general partner of Clarus
Ventures II GP, L.P.](#) 06/30/2015

[By: /s/ Robert Liptak,
Manager of Clarus Ventures II,
LLC](#) 06/30/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.